Skip to content

BRAND'S® Essence of Chicken in the Promotion of Resilience and Resistance to Stress-associated Cognitive Inhibition

The Effectiveness of BRAND'S® Essence of Chicken in the Promotion of Resilience and Resistance to Stress-associated Cognitive Inhibition

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02166931
Enrollment
100
Registered
2014-06-18
Start date
2014-03-31
Completion date
2019-09-18
Last updated
2019-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognition, Essence of Chicken, Immunity, Metabolism, Stress Associated Cognitive Inhibition

Keywords

Essence of Chicken, stress, cognitive function

Brief summary

The purpose of this study is to determine whether BRAND'S® Essence of Chicken are effective in the promotion of resilience and resistance to stress-associated cognitive inhibition.

Detailed description

This is a placebo-controlled, randomized, double-blind trial. There will be 100 subjects. Subjects are randomly assigned into either placebo or BRAND'S® Essence of Chicken (BEC), 70cc daily for 2 weeks, group. Stress test, cognitive function assessment and blood tests will be carried out at Week 0, Week 2, and Week 4 (2 weeks after termination of supplementation). The primary end-point is the better improvement of cognitive function after supplement with BEC than placebo. The second endpoints include improvement of global health survey and changes of biomarkers related to stress and immunity.

Interventions

DIETARY_SUPPLEMENTChicken Essence

BRAND'S® Chicken Essence of 70cc daily for 2 weeks Placebo 70 cc daily for 2 weeks

Sponsors

Taipei Medical University Shuang Ho Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* aged over 20 years, * mildly stressed with Perceive Stress Scale (PSS) score higher than 25 * All the participants should not require medication for their mood disturbance affected by stress during the trial.

Exclusion criteria

* history of chronic diseases * any psychiatric or neurological diseases (e.g. depression) * other medical illnesses (e.g. stroke, diabetes, other cardiovascular diseases) * allergy history to chicken

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in cognitive function at week 2 and week 4baseline, week 2, week 4Working memory, Episodic memory, Attention

Secondary

MeasureTime frameDescription
Change from baseline in biomarkers and and immunity related to stress at week 2 and week 4baseline, week 2, week 4ACTH, Cortisol, Melatonin, Glucose, BUN/CRE, GOT/GPT

Other

MeasureTime frameDescription
Change from baseline in global health survey at week 2 and week 4baseline, week 2, week 4chinese version of SF36

Countries

Taiwan

Contacts

Primary ContactMing-Show Hsieh, R.N.
13508@s.tmu.edu.tw886-2-22490088
Backup ContactChaur-Jong Hu, M.D.
chaurjongh@tmu.edu.tw886-2-22490088

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026